Evelo Biosciences

company

About

Evelo Biosciences develops oral biologics with systemic therapeutic effects.

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$45M
Industries
Biotechnology,Health Care,Medical,Therapeutics
Founded date
Jan 1, 2015
Number Of Employee
101 - 250
Operating Status
Active
Stock Symbol
nasdaq:EVLO
Legal Name
Evelo Biosciences, Inc.

Evelo Biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. Monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. These new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. Monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. By finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, Evelo can improve the speed, cost and success of drug discovery and development. Evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. Evelo Biosciences was conceived and created within VentureLabs®, Flagship Pioneering’s institutional innovation foundry, and launched by Flagship in 2015.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
7
$411.50M
Evelo Biosciences has raised a total of $411.50M in funding over 2 rounds. Their latest funding was raised on Dec 16, 2022 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 16, 2022 Post-IPO Debt $45M 1 Horizon Technology Finance Detail
Jan 29, 2021 Post-IPO Equity $67.50M Detail
May 9, 2018 IPO $85M Detail
Apr 30, 2018 Series Unknown $47.50M 1 Dementia Discovery Fund Detail
Feb 22, 2018 Series C $81.50M Detail

Investors

Number of Lead Investors
Number of Investors
4
7
Evelo Biosciences is funded by 7 investors. Horizon Technology Finance and Dementia Discovery Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Horizon Technology Finance Yes Post-IPO Debt
Dementia Discovery Fund Yes Series Unknown
Flagship Pioneering Yes Series B
Alexandria Venture Investments Series B
Celgene Series B
GV Series B
Mayo Clinic Ventures Series B

Employee Profiles

Number of Employee Profiles
22
Evelo Biosciences has 22 current employee profiles, including Advisor Brett R. Blackman
Executive
Executive
Executive
Executive

Acquisition

Evelo Biosciences has acquired 1 organizations. Their most recent acquisition was Epiva on Jul 12, 2016. They acquired Epiva for 0.

Date Company Name
Industry Acquisition Type Price
Jul 12, 2016 Epiva
Biopharma acquisition Detail